ALNY Alnylam Pharmaceuticals, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ALNY Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$313.41
Analyst Target
$457.0
+45.8%
Upside
52W High
$495.55
52W Low
$205.87
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$41.57B
P/E
135.09
ROE
73.3%
Profit margin
8.4%
Debt/Equity
3.76
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ALNY's Piotroski F-Score of 4/9 indicates weak financial health, falling into the 'Weak' range, which raises concerns despite strong profitability and growth metrics. The company trades at a premium valuation with a P/E of 135.09 and Price/Sales of 11.19, significantly above sector averages, suggesting high growth expectations are already priced in. Insider selling activity totaling $11.62M over six months signals bearish sentiment from within the company, particularly from senior officers. While revenue growth is impressive at 84.9% YoY and ROE is exceptionally high at 73.28%, the lack of earnings consistency and negative free cash flow (implied by missing data) undermine sustainability. The Graham Number of $17.64 and intrinsic value of $16.24 are far below the current price of $313.41, indicating severe overvaluation unless future growth materializes at extraordinary rates.
Key Strengths
Exceptionally high ROE of 73.28%, indicating efficient use of equity capital
Strong gross margin of 81.64% reflecting pricing power and cost control
Impressive 84.9% YoY revenue growth, signaling robust market demand
Positive earnings surprises in multiple quarters, including a 281.9% beat in Q4 2023
Analyst consensus is 'buy' with a target price of $457.00, implying upside potential
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health, with potential red flags in profitability consistency and cash flow
Debt/Equity ratio of 3.76 is high for a biotech firm, suggesting elevated financial leverage
Insider selling of $11.62M in six months, particularly from CEO and CFO, signals internal skepticism
Current price of $313.41 is over 17x the Graham Number ($17.64), indicating extreme overvaluation
Missing Free Cash Flow and Operating Cash Flow data raises concerns about capital efficiency and sustainability
AI Fair Value Estimate
Based on comprehensive analysis
$16.24
-94.8% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
38
Weak
25
75
60
30
0
AI Verdict
cautious
Key drivers: High revenue growth and strong margins, Weak Piotroski F-Score and high debt, Extreme valuation relative to intrinsic value, Bearish insider activity, Missing cash flow data
Confidence
85%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- High ROE and gross margin support long-term value potential
- Strong growth trajectory justifies premium valuation in theory
Watchpoints
- P/E of 135.09 is 730% above sector average
- Price/Sales of 11.19 is extremely high for a biotech
- Graham Number ($17.64) and Intrinsic Value ($16.24) are vastly below current price
- No dividend or cash flow support for value
Future
75/100
Ref Growth rates
Positives
- 84.9% YoY revenue growth indicates strong market traction
- Recent earnings surprises show potential for upside
- High forward P/E of 21.56 suggests growth is still expected
Watchpoints
- Most recent Q/Q EPS growth is -56.9%, indicating deceleration
- Year-over-year EPS growth of +1983.3% is unsustainable
- No PEG ratio available, but high growth at high valuation increases risk
Past
60/100
Ref Historical trends
Positives
- 25.57% average earnings surprise over last 4 quarters
- Multiple quarters with surprise beats exceeding 60%
- Consistent revenue growth over multiple years
Watchpoints
- Frequent negative surprises in prior quarters (e.g., -49.4% in Q2 2022)
- Inconsistent earnings performance despite revenue growth
- Negative EPS in most quarters, indicating high R&D and operational costs
Health
30/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 2.76 and quick ratio of 2.51 indicate strong short-term liquidity
- High gross margin supports operational resilience
Watchpoints
- Piotroski F-Score of 4/9 is in the 'Weak' range, indicating financial instability
- Debt/Equity of 3.76 is very high for a biotech (sector avg: 2.65)
- No Altman Z-Score provided, but high leverage and negative cash flow risk suggest distress potential
- Missing total cash and debt data prevents full assessment
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Payout ratio is 0.00%
- Dividend strength is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$313.41
Analyst Target
$457.0
Upside/Downside
+45.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ALNY and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Primary
|
+114.5% | +67.5% | +29.6% | -32.7% | -2.8% | -2.3% |
|
ARGX
argenx SE
Peer
|
+120.6% | +95.7% | +20.5% | -7.4% | -16.1% | -2.4% |
|
ALC
Alcon Inc.
Peer
|
+8.8% | +9.9% | -9.6% | -12.6% | +0.1% | +1.6% |
|
A
Agilent Technologies, Inc.
Peer
|
+11.4% | -11.3% | -10.7% | +12.8% | -2.2% | -3.3% |
|
EW
Edwards Lifesciences Corporation
Peer
|
+5.0% | +13.6% | +30.4% | +10.6% | +18.3% | +3.5% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
135.09
Forward P/E
21.56
PEG Ratio
N/A
P/B Ratio
52.57
P/S Ratio
11.19
EV/Revenue
11.21
EV/EBITDA
74.7
Market Cap
$41.57B
Profitability
Profit margins and return metrics
Profit Margin
8.45%
Operating Margin
12.01%
Gross Margin
81.64%
ROE
73.28%
ROA
6.81%
Growth
Revenue and earnings growth rates
Revenue Growth
+84.9%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
3.76
High debt
Current Ratio
2.76
Strong
Quick Ratio
2.51
Excellent
Cash/Share
$21.93
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-12
$1.25
-16.5% surprise
2025-10-30
$2.9
+66.1% surprise
2025-07-31
$-0.51
+27.1% surprise
Healthcare Sector Comparison
Comparing ALNY against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
P/E Ratio
135.09
This Stock
vs
164.56
Sector Avg
-17.9%
(Discount)
Return on Equity (ROE)
73.28%
This Stock
vs
-52.77%
Sector Avg
-238.9%
(Below Avg)
Profit Margin
8.45%
This Stock
vs
-20.78%
Sector Avg
-140.7%
(Weaker)
Debt to Equity
3.76
This Stock
vs
6.16
Sector Avg
-39.0%
(Less Debt)
Revenue Growth
84.9%
This Stock
vs
137.39%
Sector Avg
-38.2%
(Slower)
Current Ratio
2.76
This Stock
vs
3.36
Sector Avg
-17.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
BEARISH | $41.57B | 135.09 | 73.3% | 8.4% | $313.41 | |
|
ARGX
argenx SE
|
BULLISH | $43.35B | 35.74 | 20.2% | 30.4% | $700.45 | |
|
ALC
Alcon Inc.
|
NEUTRAL | $39.59B | 38.6 | 4.8% | 10.3% | $80.29 | |
|
A
Agilent Technologies, Inc.
|
NEUTRAL | $38.29B | 30.28 | 20.6% | 18.8% | $135.05 | |
|
EW
Edwards Lifesciences Corporation
|
NEUTRAL | $50.08B | 37.85 | 13.5% | 23.2% | $86.3 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | FITZGERALD KEVIN JOSEPH | Officer | Sale | 1,291 | $417,685 |
| 2026-03-05 | GARG PUSHKAL | Officer | Sale | 4,713 | $1,524,796 |
| 2026-03-04 | GREENSTREET YVONNE L | Chief Executive Officer | Sale | 2,933 | $947,581 |
| 2026-03-04 | TANGULER TOLGA | Officer | Sale | 2,309 | $745,984 |
| 2026-03-04 | POULTON JEFFREY V | Chief Financial Officer | Sale | 2,468 | $797,351 |
| 2026-03-03 | FITZGERALD KEVIN JOSEPH | Officer | Sale | 3,250 | $1,051,773 |
| 2026-03-03 | GARG PUSHKAL | Officer | Sale | 3,492 | $1,130,131 |
| 2026-03-02 | GREENSTREET YVONNE L | Chief Executive Officer | Sale | 6,799 | $2,227,698 |
| 2026-03-02 | TANGULER TOLGA | Officer | Sale | 1,598 | $523,584 |
| 2026-03-02 | POULTON JEFFREY V | Chief Financial Officer | Sale | 2,206 | $722,801 |
| 2026-03-02 | FITZGERALD KEVIN JOSEPH | Officer | Stock Award | 3,688 | - |
| 2026-03-02 | GARG PUSHKAL | Officer | Stock Award | 4,769 | - |
| 2026-03-02 | TANGULER TOLGA | Officer | Stock Award | 4,769 | - |
| 2026-03-02 | GREENSTREET YVONNE L | Chief Executive Officer | Stock Award | 13,844 | - |
| 2026-03-02 | SUPRAN BRYAN | Officer | Stock Award | 1,539 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
25 analysts
HC Wainwright & Co.
2026-02-18
Buy
Buy
Freedom Capital Markets
2026-02-17
Hold
Buy
Canaccord Genuity
2026-02-17
Buy
Buy
Chardan Capital
2026-02-13
Buy
Buy
Needham
2026-02-12
Buy
Buy
Morgan Stanley
2026-01-30
Equal-Weight
Equal-Weight
B of A Securities
2026-01-30
Buy
Buy
HC Wainwright & Co.
2026-01-30
Buy
Buy
Barclays
2026-01-28
Overweight
RBC Capital
2026-01-20
Outperform
Outperform
Past News Coverage
Recent headlines mentioning ALNY from our newsroom.
Newest → oldest
No matching news yet.